angiogenic gene therapy


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia, Wikipedia.

Agent

AGENT
Angiogenic GENe Therapy. A clinical trial evaluating the safety & efficacy of an angiogenic gene therapy, Ad5-FGF4 (fibroblast growth factor 4).
Primary endpoint 1-month, 3-month exercise tolerance.
Conclusion Early data indicate that Ad5-FGF4 significantly improves exercise time in treated patients.

Agent
Choice in dying An adult appointed by the declarant, under an advance directive executed or made in accordance with the legal provisions, to make health care decisions for the declarant. VA Bd of Medicine, 1997-98 § 54.1-2982
Epidemiology A factor (such as a microorganism, chemical substance, or form of radiation) whose excessive presence, or relative absence (in deficiency states), is essential for the occurrence of a disease.
Health insurance An insurance company representative licensed by the state who solicits, negotiates, or effects insurance contracts and who provides services to the policyholder for the insurer.
Infomatics A small mobile piece of computer software that can send itself across a computer network and perform a task on a remote machine.
Medspeak A thing capable of producing an effect.
Military A code term for a biological substance that can be used as a weapon of mass destruction.
Nutrition A substance added to a food to change a physical property.
Pharmaceutical industry An authorised person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser, not including a common or contract carrier, public warehouseman, or employee of the carrier warehouseman. VA Bd of Pharmacy, 7/97.
Pharmacology Any substance capable of producing a physical, chemical or biologic effect.
Virology An unidentified virus or pathogen.

angiogenic gene therapy

Cardiology An investigational therapy that delivers a growth factor gene to diseased coronary arteries evoking growth factor production and stimulating angiogenesis and formation of blood vessels that bypass occluded coronary arteries
Mentioned in ?
References in periodicals archive ?
In the second quarter 2014, Cardium reported positive interim Phase 3 data from the international ASPIRE clinical study showing significant potential efficacy of Generx angiogenic gene therapy for myocardial ischemia due to coronary artery disease.
In March 2000, the company reported positive results from a double-blind, placebo-controlled Phase 1/2 clinical trial of its lead product, GENERX, a non-surgical angiogenic gene therapy, and plans to begin larger scale clinical studies.
an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of patients with cardiac microvascular insufficiency and myocardial ischemia due to advanced coronary artery disease; and (2) Excellagen[sup.
The new data from the international Phase 3 ASPIRE clinical study further supports findings of safety and efficacy from the four prior and published Generx angiogenic gene therapy (AGENT) clinical studies that have been conducted at over 100 medical centers worldwide.
an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of patients with cardiac microvascular insufficiency with myocardial ischemia due to advanced coronary artery disease; and (2) Excellagen[sup.
The Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is an angiogenic gene therapy that is being developed as a pioneering treatment for Cardiac Microvascular Insufficiency or CMI in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to advanced coronary artery disease (CAD).
an interventional cardiology angiogenic gene therapy product candidate for the potential treatment of cardiac microvascular insufficiency due to advancing coronary artery disease, which is the subject of an international Phase 3 registration clinical study, and (2) Excellagen[sup.
an interventional cardiology, angiogenic gene therapy product candidate for the treatment for cardiac microvascular insufficiency due to advancing coronary artery disease and, (2) Excellagen[sup.